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Restrictive dermopathy (RD) is a lethal human genetic disorder characterized by very tight, thin, easily eroded skin,
rocker bottom feet, and joint contractures. This disease was recently reported to be associated with a single
heterozygous mutation in ZMPSTE24 and hypothesized to be a digenic disorder (Navarro et al, Lamin A and
ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal
laminopathy. Hum Mol Genet 13:2493–2503, 2004). ZMPSTE24 encodes an enzyme necessary for the correct
processing and maturation of lamin A, an intermediate ﬁlament component of the nuclear envelope. Here we
present four unrelated patients with homozygous mutations in ZMPSTE24 and a ﬁfth patient with compound
heterozygous mutations in ZMPSTE24. Two of the three different mutations we found are novel, and all are single
base insertions that result in messenger RNA frameshifts. As a consequence of the presumed lack of ZMPSTE24
activity, prelamin A, the unprocessed toxic form of lamin A, was detected in the nuclei of both cultured cells and
tissue from RD patients, but not in control nuclei. Abnormally aggregated lamin A/C was also observed. These
results indicate that RD is an autosomal recessive laminopathy caused by inactivating ZMPSTE24 mutations that
result in defective processing and nuclear accumulation of prelamin A.
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Restrictive dermopathy (RD), also known as lethal tight skin
contracture syndrome (MIM 275210), is a rare genetic dis-
order that results in death, usually within several hours or
days of birth. Babies with RD have tight, translucent, par-
tially eroded skin, joint contractures, rocker bottom feet,
and distinctive craniofacial abnormalities that typically in-
clude micrognathia, a facial expression with the mouth fixed
in an ‘‘O’’ position, a small pinched nose, and low-set ears
(Welsh et al, 1992; Mau et al, 1997; Sillevis Smitt et al, 1998).
In most patients, death results from respiratory distress as a
result of severely restricted movements.
Of the few RD cases reported in the literature, many arose
in children of consanguineous parents, and the disease re-
curs within families; its mode of inheritance had therefore
been presumed to be autosomal recessive (Welsh et al,
1992; Sillevis Smitt et al, 1998). Recently, however, Navarro
et al (2004) used a candidate gene approach to identify a
single inactivating heterozygous mutation in ZMPSTE24
(c.1085dupT) associated with RD in six unrelated, noncon-
sanguineous families of French and Dutch heritage.
ZMPSTE24 encodes a zinc metalloproteinase required
for lamin A maturation (Bergo et al, 2002; Pendas et al,
2002), suggesting that RD is a laminopathy that affects the
structure of the nucleus. Because only one allele was found
to be mutated in each affected individual, and the parents
carrying that allele were normal, the authors hypothesized a
digenic mode of inheritance for RD (Navarro et al, 2004).
Contrary to this, we have identified four patients with three
different homozygous mutations and one patient with com-
pound heterozygous mutations in ZMPSTE24 that are as-
sociated with RD, providing strong support for a simple
autosomal recessive mode of inheritance. We also show
that in two patients with different homozygous mutations,
there are nuclear abnormalities associated with accumula-
tion of unprocessed prelamin A, thereby providing novel
evidence that RD is a laminopathy.
Results
Identiﬁcation of ZMPSTE24 mutations associated with
RD We became interested in RD upon discovering a
spontaneous, autosomal recessive mouse mutation that
we named wrinkle free (wrfr). wrfr / mice have very tight,
thick skin, and their mouths are fixed in an open position
(Moulson et al, 2003). They die within 24 h of birth from
an inability to breathe properly or to suckle, because of
Abbreviations: DHPLC, denaturing high-performance liquid chro-
matography; FACE, farnesyiated protein-converting enzyme 1;
mRNA, messenger RNA; PBS, phosphate-buffered saline; PCR,
polymerase chain reaction; RD, restrictive dermopathy; SNP, single
nucleotide polymorphism
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severely restricted movements. The overall phenotype is
thus reminiscent of RD. Positional cloning of wrfr revealed a
retrotransposon insertion in Slc27a4, which encodes fatty
acid transport protein 4 (Moulson et al, 2003).
In an effort to determine whether SLC27A4 plays a role in
human RD, we obtained blood and/or tissues from mem-
bers of six RD kindreds, three of which were known or
suspected to involve consanguinity. DNA was prepared
from individuals with RD, all of whom died within hours or
days of birth and exhibited the classic features described by
Witt (Witt et al, 1986). DNA was also prepared from parents
and any unaffected full siblings when available. We se-
quenced SLC27A4 exons and intron–exon junctions in three
unrelated patients but found no mutations. To formally rule
out SLC27A4 as a candidate, and to identify potential can-
didate regions, we performed genome-wide single nucleo-
tide polymorphism (SNP) genotyping using Affymetrix
GeneChip Mapping arrays (Matsuzaki et al, 2004) on a
small but potentially informative subset of these DNA (data
not shown). Using DNA-Chip (dCHIP) software (Lin et al,
2004) to display the results, and assuming an autosomal
recessive mode of inheritance, we identified a 15 Mb locus
on chromosome 1p32–35 as a major RD candidate region,
whereas the SLC27A4 locus at 9q34 was ruled out. Con-
sistent with the report of Navarro et al, 1p32–35 contains
ZMPSTE24. Therefore, we sequenced ZMPSTE24 exons
and flanking intronic sequences amplified by polymerase
chain reaction (PCR) from RD family members’ DNA
to search for mutations and to determine their association
with RD.
A consanguineous Dutch family had one child affected
with RD and five unaffected children. We identified in this
family the same c.1085dupT insertion reported by Navarro
et al (2004) (Fig 1A and B). In contrast to the findings of
Navarro et al, however, here the mutation was homozygous
in the affected patient, whereas both parents were het-
erozygous (Fig 1A and B). DNA was also available from four
of the five unaffected siblings; three were heterozygous for
the insertion, and one did not carry it. We found this same
mutation in a nonconsanguineous American family of Ger-
man ancestry (Fig 1C). The mutation was homozygous in
one affected child, and both parents and one brother were
heterozygous; the other brother did not carry the mutation.
No DNA from the second affected child was available. In
this family, the apparently identical mutations were linked to
different genotypes at a novel SNP in ZMPSTE24 intron 4
(data not shown), suggesting that the mutations arose
independently.
Analysis of ZMPSTE24 in a consanguineous Guatemalan
family with two affected children revealed a novel single
base duplication in exon 5 (c.591dupT) (Fig 1D and E). This
mutation was homozygous in one affected child and het-
erozygous in both parents (Fig 1D and E). DNA from the
second child was not available.
A novel single base duplication was present in
ZMPSTE24 exon 1 (c.54dupT) in a Mennonite kindred with
five affected children out of six born to two families (Fig 1F
and G). DNA was only available from one affected child; the
mutation was homozygous in her and heterozygous in both
her parents. The other parents and their unaffected son
were heterozygous for the same mutation. RD has been
reported in a Mennonite kindred before (Lowry et al, 1985),
suggesting that this unique mutation is segregating in the
Mennonite population.
We also assayed DNA extracted from archived paraffin-
embedded tissues taken from a Dutch RD patient. Two dif-
ferent heterozygous mutations were detected: the exon 5
mutation found in the Guatemalan family (c.591dupT) and
the previously identified exon 9 insertion (c.1085dupT). We
conclude that this patient is compound heterozygous, al-
though we cannot formally prove it because parental DNA
are not available.
Might these mutations actually be common polymorph-
isms? The c.1085dupT mutation in exon 9 has been pre-
viously reported, and it was not found to be present on 300
control chromosomes (Agarwal et al, 2003; Navarro et al,
2004). Denaturing high-performance liquid chromatography
(DHPLC) analysis of exons 1 and 5 amplified by PCR
from 50 CEPH grandparent DNA showed no evidence of
the c.54dupT and c.591dupT mutations, respectively (data
not shown). Searches of the Celera Discovery System
(http://myscience.appliedbiosystems.com/) and public SNP
(http://www.ncbi.nlm.nih.gov/SNP/) databases did not re-
veal any insertions in the ZMPSTE24 coding region, al-
though 470 SNP have been identified in the gene. Together
with the fact that all three sequence variants shift the mes-
senger RNA (mRNA) reading frame, these findings suggest
that they are genuine pathogenic mutations.
Consequences of the mutations on expression of
ZMPSTE24 All three mutations are single base duplications
in ZMPSTE24 coding exons. They are therefore frameshift
mutations that would be expected to lead to production of
truncated versions of ZMPSTE24, which normally consists
of 475 amino acids. c.54dupT would encode p.Ile19-
TyrfsX28; c.591dupT would encode p.Ile198TyrfsX20; and
c.1085dupT would encode p.Leu362PhefsX19, according
to standard nomenclature (den Dunnen and Antonarakis,
2000; see also http://www.genomic.unimelb.edu.au/mdi/
mutnomen/recs.html). These truncated proteins would
be expected to have little if any normal function, as
ZMPSTE24 is conserved in terms of both sequence and
enzymatic activity from yeast to humans. Indeed, human
ZMPSTE24 can complement the yeast ste24 mutation
(Schmidt et al, 2000), but p.Leu362PhefsX19, which is en-
coded by the c.1085dupT mutation, is noncomplementing
(Agarwal et al, 2003).
Aside from encoding truncated proteins, the mutant
transcripts might also be subject to nonsense-mediated
mRNA decay (NMD) (Hentze and Kulozik, 1999), which
could preclude synthesis of any truncated ZMPSTE24 pro-
teins. To assay for NMD, we analyzed RNA isolated from
fibroblasts derived from the American patient carrying the
c.1085dupT mutation and from a control. Northern blotting
did not reveal a significant decrease in ZMPSTE24 mRNA
levels in the RD fibroblasts (data not shown), suggesting
that NMD was not a major factor. One possibility to explain
this is that exon 9 containing the frameshift might be
skipped, leading to an in-frame splice from exon 8 to exon
10 and elimination of the premature stop codon. But reverse
transcriptase-polymerase chain reaction (RT-PCR) analysis
did not reveal any evidence for skipping of exon 9 (Fig 2A).
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RNA was also prepared from the liver of the Guatemalan
patient, but it was highly degraded and not suitable for
northern blotting. Nevertheless, RT-PCR analysis revealed
that there was no in-frame skipping of the mutated exon 5
(Fig 2A), which could have led to production of a protein.
Consistent with these RT-PCR data, western blotting with a
ZMPSTE24 COOH-terminal antibody detected little if any
ZMPSTE24 in patient fibroblasts or liver, but an appropriate
50 kDa band was observed in controls (Fig 2B).
Consequences of the mutations on localization of nu-
clear envelope proteins The only known substrate for
ZMPSTE24 is lamin A, encoded by the LMNA gene. This
gene also encodes lamin C, a shorter form that is translated
Figure 1
Family pedigrees, ZMPSTE24 genotypes, and sequence chromatograms. Arrows indicate individuals whose DNA was tested. ZMPSTE24
mutations are shown below the pedigree symbols; all are hypothesized to cause loss of activity. (A) Pedigree of a consanguineous Dutch family; the
father’s maternal grandmother and the mother’s paternal grandmother were sisters. The affected child had a homozygous thymidine duplication in
ZMPSTE24 exon 9. (B) Sequence chromatograms of exon 9 (reverse direction) show a duplicated thymidine in a stretch of nine. Overlap of the
normal and mutated strand sequences occurred after the insertion in this and in all the other heterozygous samples described. (C) Pedigree of a
nonconsanguineous American family carrying the same mutation as the Dutch family. (D) Pedigree from a consanguineous Guatemalan family; the
father’s paternal grandfather was a paternal uncle of the mother. (E) Sequence chromatograms of exon 5 (forward direction) show a duplicated
thymidine in a stretch of seven. (F) Five affected children were born to two pairs of related parents from a Mennonite kindred; the fathers were
brothers of each other, and the mothers were first cousins of each other. (G) Sequence chromatograms of ZMPSTE24 exon 1 (reverse direction)
show an extra thymidine homozygous in the affected child.
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from an alternatively spliced mRNA. Lamin A maturation
requires ZMPSTE24 activity, but lamin C maturation does
not. Lamin A/C distribution is abnormal in RD patients re-
ported to have a heterozygous c.1085dupT mutation in
ZMPSTE24 (Navarro et al, 2004). Because the c.1085dupT
mutation in the patient from whom we obtained fibroblasts
was homozygous, we examined whether there was aberrant
distribution of lamin A/C using an antibody that recognizes
both (Fig 3A, B). Lamin A/C appeared to be distributed in
clusters in the nucleus, as opposed to the homogeneous,
smooth, uniform distribution in nuclei from normal fibroblast
cultures.
Accumulation of unprocessed prelamin A, which is toxic
(Fong et al, 2004), has been reported in Zmpste24 knockout
mice (Bergo et al, 2002; Pendas et al, 2002). To examine
whether there was accumulation of prelamin A in RD pa-
tients as well, cultured fibroblasts were stained with a pre-
lamin A-specific antibody. Strong prelamin A staining was
observed in RD fibroblast nuclei (Fig 3D), whereas no pre-
lamin A was detected in control fibroblasts (Fig 3C). Nuclear
prelamin A was also observed in frozen liver sections from
the Guatemalan patient (Fig 3F) but not in liver from a con-
trol, although lamin A/C was clearly present (Fig 3E). The
presence of prelamin A in patient but not control liver
was confirmed by western blotting (Fig 2C). We conclude
that RD is associated with a specific defect in prelamin
A processing caused by the absence of functional
ZMPSTE24.
Discussion
In this study, we identified two novel mutations and a third
previously described mutation in ZMPSTE24 that are as-
sociated with RD. Importantly, we also show that RD is a
simple autosomal recessive disorder. Though ZMPSTE24
had already been implicated in RD, only one heterozygous
mutation was identified, and it was also present in unaf-
fected family members, leading to the conclusion that RD
Figure 2
Analysis of ZMPSTE24 messenger RNA (mRNA) and protein in
control and restrictive dermopathy (RD) samples. (A) Reverse tran-
scriptase polymerase chain reaction analysis of total RNA from liver
and fibroblasts reveals no evidence of splicing around the exons con-
taining the c.591dupT (exon 5; lanes 1 and 2) and c.1085dupT (exon 9;
lanes 5 and 6) mutations. Glyceraldehyde-3-phosphate dehydrogenase
primers were used as a control in lanes 3, 4, 7, and 8. Control fetal liver,
lanes 1 and 3; c.591dupT liver, lanes 2 and 4; control fibroblasts, lanes 5
and 7; c.1085dupT fibroblasts, lanes 6 and 8. (B) Western blot analysis
of ZMPSTE24 (top) and b-actin (bottom). ZMPSTE24 was detected in
control but not RD extracts; the same blot reprobed for b-actin shows
protein in all lanes. Lane 1, control fetal liver; Lane 2, RD liver (Gua-
temalan patient); Lane 3, control fibroblasts; Lane 4, RD fibroblasts
(American patient). (C) Western blot analysis of prelamin A and b-actin.
Prelamin A (  70 kDa) was detected in liver from the RD patient (lane
2) but not from the control (lane 1). The blot was reprobed for b-actin to
show that protein was present in both lanes.
Figure3
Immunofluorescent localization of lamin A/C and prelamin A in
control and restrictive dermopathy (RD) samples. The organization
of lamins in fibroblast nuclear envelopes is disrupted by accumulation
of prelamin A in the absence of ZMPSTE24. Confocal micrographs
show localization of lamins A and C in nuclei of a control fibroblast (A)
and a fibroblast from the American RD patient (B). Prelamin A was
undetectable in control fibroblasts (C), but there was nuclear accumu-
lation in RD patient fibroblasts (D). In liver sections, prelamin A was
undetectable in the control (E) but clearly present in RD patient nuclei
(F). The control section did contain nuclei, which are stained for lamin
A/C (inset in E).
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was a digenic disorder (Navarro et al, 2004). Rather than
there being a digenic mode of inheritance, we favor the pos-
sibility that there exist ZMPSTE24 mutations that are diffi-
cult to detect by conventional PCR-based methods. This is
perhaps the most straightforward explanation for how there
could be an absence of mature lamin A even with one ap-
parently wild-type copy of ZMPSTE24. Such mutations
could lie in the gene’s promoter, or could involve segmental
deletions that are complemented—only as far as PCR is
concerned—by normal regions of the other allele. Indeed,
we could not find any mutations in a pair of affected fra-
ternal twins from Finland, though SNP genotyping showed
that the twins share genotypes on the segment of chromo-
some 1 containing the ZMPSTE24 locus (data not shown).
All mutations identified thus far to cause RD are single
base duplications that result in mRNA frameshifts, which
likely prevent production of a functional protein. One mis-
sense ZMPSTE24 mutation (c.1018T4C; p.Trp340Arg) has
been found, however, in a Belgian patient with severe man-
dibuloacral dysplasia with type B lipodystrophy (MADB—
MIM 608612) (Agarwal et al, 2003). This patient was actually
compound heterozygous; the other allele bore the same
c.1085dupT-inactivating mutation that Navarro et al (2004)
and we have subsequently found to be associated with RD.
The mutant protein carrying the p.Trp340Arg substitution is
partially active in yeast complementation assays, whereas
p.Leu362PhefsX19, which is encoded by c.1085dupT, is
totally inactive (Agarwal et al, 2003). Thus, the limited infor-
mation available regarding ZMPSTE24 mutations suggests
that inactivating mutations cause RD, whereas partial loss
of function mutations are associated with less severe dis-
ease, as is MADB. Identification of mutations in additional
patients will help determine whether a definitive genotype/
phenotype correlation exists.
Accumulation of prelamin A has been reported in
Zmpste24 knockout mice (Bergo et al, 2002; Pendas et al,
2002) and in cultured cells from human patients with Hut-
chinson–Gilford progeria syndrome (HGPS) (MIM 176670)
(Goldman et al, 2004); its presence has also been hypoth-
esized but not proved in other human laminopathies
(Agarwal et al, 2003; Navarro et al, 2004). Our study dem-
onstrates accumulation of prelamin A in affected human
tissue in situ (Fig 3F), suggesting that it is not merely a
consequence of cell culture. Accumulation of prelamin A
has recently been shown to be toxic; disease phenotypes in
Zmpste24 / mice are ‘‘rescued’’ by only a 50% reduction
in the amount of prelamin A, via knockout of one Lmna allele
(Fong et al, 2004). The presence of large amounts of pre-
lamin A may also account for the increased severity of RD
as compared with laminopathies with either lamin A muta-
tions or a missense mutation in ZMPSTE24. Given the lack
of detectable nuclear prelamin A in normal cells, it is pos-
sible that a simple immunofluorescence assay for prelamin
A in amniocyte and/or chorionic villi cell nuclei, in conjunc-
tion with DNA analysis, might serve as a definitive prenatal
test for RD and perhaps for other laminopathies. Preim-
plantation genetic diagnosis (Sermon et al, 2004) should
also be possible. Further studies will be necessary to de-
termine the feasibility of these approaches.
We found lamins A and C clustered and distributed in
aggregates in the nuclei of RD patient fibroblasts, whereas
normal fibroblast nuclei showed a homogeneous and
smooth, even distribution, concentrated at the nuclear
periphery. Abnormal distribution of lamins A and C in
foci, aggregations, and honeycombs has been reported
in a number of human patients carrying lamin A/C
gene mutations (Novelli et al, 2002; Capanni et al, 2003;
Caux et al, 2003; Muchir et al, 2004) as well as in cells
transfected with lamin A/C mutants (Ostlund et al, 2001;
Holt et al, 2003).
The mechanism whereby mutations in LMNA and
ZMPSTE24 that result in aberrant lamin A processing cause
disease has not been determined. Several lines of evidence
suggest that it is likely to be a combination of impaired
nuclear stability and the resulting nuclear deformations
(Lammerding et al, 2004) causing secondary alterations
in heterochromatin localization and significant changes in
gene expression (Nikolova et al, 2004). (For a review of
these hypotheses, see reference Worman and Courvalin
(2004).) In addition, lamin A binds directly or indirectly to a
number of nuclear proteins, including emerin (Lee et al,
2001; Sakaki et al, 2001) and nesprin (Mislow et al, 2002),
and attach them to the nuclear envelope. Lamin A also
binds to transcription factors such as MOK2 (Dreuillet et al,
2002), retinoblastoma (Mancini et al, 1994), and SREBP1
(Lloyd et al, 2002). (See (Zastrow et al, 2004) for a review of
lamin-binding proteins.) Mislocalization of lamin A, as we
and others have observed, is likely indicative that some of
its binding partners are also mislocalized and not bound to
the nuclear envelope, which may have profound secondary
effects on cells.
Interestingly, the neonatally lethal wrinkle-free phenotype
of Slc27a4 / mice that we and others have reported
(Herrmann et al, 2003; Moulson et al, 2003) appears to be
much more similar to the human RD phenotype than that
exhibited by Zmpste24 / mice, which survive for several
months. This may be coincidence, but the possibility exists
that there is some special mechanistic relationship in
humans between nuclear architecture and expression of
genes involved in fatty acid homeostasis. Indeed, one of the
features of the diverse laminopathies that are less severe
than RD is lipodystrophy.
Genetic and allelic heterogeneity appear to explain in
part the phenotypic differences among the related lamino-
pathies HGPS, MAD, and most recently, RD. Navarro et al
included in their study two patients several months old with
a skin disease less severe than typical RD, and they found
one novel and one previously reported mutation in the
LMNA gene. These are both likely to be sporadic, het-
erozygous, dominant-negative mutations. The latter muta-
tion had been found previously in several patients with
HGPS. There is clearly a marked difference in disease se-
verity between ZMPSTE24-based neonatally lethal RD and
LMNA-based progeria. To avoid confusion, we propose that
the descriptor ‘‘restrictive dermopathy’’ be reserved for
individuals with the severe, neonatally lethal disease de-
scribed by Witt (Witt et al, 1986). Children with some RD-like
features who survive well past the neonatal period are more
likely to manifest features of progeria or MAD and should be
described as such. The ability to screen for ZMPSTE24 and
LMNA mutations may make these distinctions possible at
the molecular level.
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Materials and Methods
Ampliﬁcation of genomic DNA, DNA sequencing, and
DHPLC The Washington University School of Medicine Human
Studies Committee approved this study, which was conducted
according to the Declaration of Helsinki principles. Informed pa-
rental consent was obtained in all cases, except for one that in-
volved archived tissues; for this a waiver of consent was approved.
Genomic DNA was extracted from the blood of six affected indi-
viduals from five different kindreds and from their parents and
available unaffected siblings using QiaAMP DNA Blood Kit (Qiagen
Inc., Valencia, California). DNA was extracted from paraffin-em-
bedded tissues from a seventh affected individual as described
(Coombs et al, 1999). Exons and intron–exon junctions from
genomic DNA samples were amplified using KlentaqLA (BD Bio-
sciences Clontech, Palo Alto, California). Each 20 mL reaction
contained 1  KLA (KlentaqLA) buffer, 125 mM dNTP (deoxribo-
nucleotide triphosphates) 2.5 mM MgCl2, 10 pmoles of each prim-
er, 20 ng genomic DNA, and 1 U KlentaqLA. Cycling conditions
were a 3 min initial denaturation at 951C, followed by 35 cycles of
30 s at 941C, 1 min at 571C, and 3 min at 701C. PCR products were
gel purified and recovered using the Wizard SV Gel Clean-up Sys-
tem (Promega, Madison, Wisconsin). The Washington University
Protein and Nucleic Acid Chemistry Lab performed automated
sequencing reactions using internal primers with Big-Dye Termi-
nator 3.1 and an Applied Biosystems 3730 DNA sequencer (Ap-
plied Biosystems, Foster City, California). The PCR and sequencing
primer sequences used are shown in Table SI.
For DHPLC, exons 1 and 5 were amplified from 50 CEPH
individuals and from heterozygous parents as described above.
Following denaturation and slow reannealing, amplicons were
subjected to DHPLC analysis on a Transgenomic WAVE System
containing a DNASepHT column (Transgenomic, Omaha, Nebras-
ka) in a linear acetonitrile gradient.
RNA puriﬁcation and RT-PCR Total RNA was isolated from liver
homogenized in Tri-Reagent (Molecular Research Center, Cincin-
nati, Ohio) and from fibroblasts scraped into Tri-Reagent according
to the manufacturer’s instructions. 0.5 mg of total RNA was reverse
transcribed using Superscript III (Invitrogen, Carlsbad, California)
with oligo(dT)12–18 primers in a 20 mL reaction. Touchdown PCR
was performed in a 20 mL reaction using 1 mL of complementary
DNA. PCR reactions contained manufacturer-supplied 1  reac-
tion buffer, 2.5 mM magnesium chloride, 0.125 mM of each dNTP,
10 pmoles of each primer, and 0.5 U Biolase DNA polymerase
(MidSci, St Louis, Missouri). Primers are shown in Table SII.
Western blotting Proteins were extracted from liver by sonication
in 8 M urea, 10 mM tris pH 8.0, 1 mM ethylenediaminetetraacetic
acid, and Complete Protease Inhibitors (Roche Diagnostics, India-
napolis, Indiana). Fibroblasts were scraped into cold phosphate-
buffered saline (PBS) containing protease inhibitors, pelleted,
resuspended in the urea buffer, and sonicated. Proteins were
separated on 8% sodium dodecyl sulfate-polyacrylamide gels and
blotted on to nitrocellulose. Blots were incubated in 5% nonfat dry
milk in TBST (Tris-buffered saline/0.02% Tween-20) for 1 h prior
to incubation with primary antibodies overnight at 41C. Primary
antibodies were goat anti-human prelamin A (sc-6214; Santa
Cruz Biotechnology, Santa Cruz, California), rabbit anti-human
ZMPSTE24 (AP2415b; Abgent, San Diego, California), and rabbit
anti-human b-actin (4967; Cell Signaling Technology, Beverly, Mas-
sachusetts). The secondary antibody for b-actin was conjugated
to horseradish peroxidase, whereas secondary antibodies for pre-
lamin A and ZMPSTE24 were detected with avidin–biotin and
horseradish peroxidase. Visualization was by enhanced chemilu-
minescence (Amersham, Arlington Heighst, Illinois).
Cell culture and immunoﬂuorescence Skin fibroblasts from the
American RD patient and normal skin fibroblasts (Detroit 551 from
the American Type Culture Collection, Manassas, Virginia) were
cultured in Earle’s Minimal Essential medium modified to contain
2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 1.5 g per liter sodium bicarbonate, and 10% fetal
bovine serum. For immunostaining, cells were cultured for several
days on glass Falcon BioCoat CultureSlides (BD Biosciences Dis-
covery Labware, Bedford, Massachusetts). Cells were fixed for 10
min at 41 C in 2% fresh paraformaldehyde in PBS, washed in PBS,
permeabilized for 10 min in cold methanol, and air-dried. Liver
tissue from the Guatemalan RD patient and from a control were
frozen in OCT, sectioned on a cryostat, air-dried for 30 min, and
fixed and permeabilized as described for cultured cells.
For immunofluorescence, samples were blocked in either 4%
bovine serum albumin (BSA) in PBS or 1% heat-inactivated normal
goat serum in PBS. Antibodies were as follows: anti-lamins A and
C (MAB3538) and fluorescein isothiocyanate-conjugated anti-goat
immunoglobulin G (IgG) from Chemicon (Temecula, California);
goat anti-prelamin A; and Alexa 488-conjugated anti-mouse IgG1
from Molecular Probes (Eugene, Oregon). All antibody dilutions
were in PBS containing 1% BSA, and washes were in PBS. Fol-
lowing primary and secondary antibody incubations at room tem-
perature for 1 h each and washing, slides were mounted in 1 mg
per mL p-phenylenediamine/0.1  PBS/90% glycerol.
Confocal microscope images were obtained using a Zeiss
compound microscope (Carl Zeiss International, Jena, Germany)
with a BioRad MRC 1024 confocal adaptor (BioRad Laboratories,
Inc., Hercules, California). All other micrographs were obtained
with a Spot 2 cooled color digital camera (Diagnostic Instruments,
Sterling Heights, Michigan) attached to a Nikon Eclipse E800
compound microscope (Nikon USA, Melville, New York). Images
were imported into Adobe Photoshop 5 and Adobe Illustrator 9 for
processing and layout.
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After this paper was accepted, we found a novel ZMPSTE24 nonsense
mutation, c.691G4T, predicted to encode p.Glu231X, in both parents of
an affected child from southern India. DNA from the child was not
available, but we consider this to be a pathogenic mutation.
Navarro et al. recently published a paper (Loss of ZMPSTE24 (FACE-1)
causes autosomal recessive restrictive dermopathy and accumulation of
Lamin A precursors. Hum Mol. Genet 14:1503–1513, 2005) showing that
both alleles of ZMPSTE24 are in fact mutated in their patients with
restrictive dermopathy; these patients were previously reported to carry
only heterozygous mutations. Based on these new findings, they have
withdrawn their hypothesis of digenic inheritance.
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